Highest-materiality recent filing
NeuroOne files prospectus to sell up to $13.4M in common stock via ATM program with JonesTrading
Updated prospectus supplement filed June 12, 2026 for at-the-market offering of up to $13.4M of common stock.
NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance
Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.
NeuroOne Q2 product revenue up 72% to $2.4M; net loss narrows to $2.1M
Product revenue $2.4M (+72% YoY); no license revenue vs $3.0M in prior year first half.
NeuroOne regains Nasdaq compliance as bid price holds above $1 for 10 days
Received Nasdaq deficiency letter on May 6, 2025 for bid price below $1 for 30 consecutive days.
CFO Ronald McClurg to retire June 30, 2026; COO Christopher Volker to succeed as CFO
Ronald McClurg to retire as CFO effective June 30, 2026, then serve as Senior Advisor until Dec 31, 2026.
NeuroOne to effect 1-for-6 reverse stock split to regain Nasdaq compliance
Board approved 1-for-6 reverse stock split, effective 5:00 p.m. ET on April 15, 2026.
NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan
Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.
NeuroOne sets 2026 annual meeting for April 3; shareholder proposals due March 4
Annual meeting scheduled for April 3, 2026; date moves more than 30 days from 2025 meeting.
NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M
Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).
NeuroOne appoints Jason Mills, Penumbra EVP of Strategy, to Board of Directors
Board size increased to five; Mills appointed as Class I director effective Dec 18, 2025.
NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%
Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.
NeuroOne Medical receives Nasdaq extension to May 4, 2026 to regain $1.00 bid price compliance
Nasdaq granted a 180-day extension until May 4, 2026 for minimum bid price compliance.
NeuroOne reports preliminary FY2025 product revenue of $9.1M, up 163% from $3.5M in FY2024
Preliminary unaudited FY2025 product revenue $9.1M, a record; FY2024 was $3.5M.
NeuroOne receives FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System
FDA 510(k) clearance granted for OneRF Trigeminal Nerve Ablation System.
NeuroOne files prospectus supplement for up to $6.75M ATM offering via JonesTrading
Filed updated Prospectus Supplement on Aug 15, 2025 for up to $6.75M of common stock via ATM.
NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed
Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).
NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%
Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.
NeuroOne receives Nasdaq deficiency notice for bid price below $1.00
Closing bid price was below $1.00 for 30 consecutive business days; 180-day cure period ends Nov. 3, 2025.
NeuroOne raises $8M in underwritten public offering of 16M shares at $0.50/share
Offered 16,000,000 shares at $0.50 per share; underwriter option for additional 2,400,000 shares.
NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split
Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.
Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.
David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.
NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance
Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.
NeuroOne regains Nasdaq compliance; reports record preliminary Q1 revenue of $6.2M
Received Nasdaq letter on Feb 3, 2025 confirming cure of bid price deficiency; hearing cancelled.
NeuroOne issues shareholder letter; no specific financial or operational metrics disclosed
CEO Dave Rosa discusses company achievements, progress, and strategy in letter dated Jan 14, 2025.
NeuroOne reports preliminary Q1 FY2025 revenue of $6.2M, up from $1.0M YoY
Preliminary unaudited Q1 FY2025 total revenue $6.2M vs $1.0M in Q1 FY2024.
NeuroOne receives Nasdaq delisting determination for bid price non-compliance; intends to appeal
Received delisting determination from Nasdaq on Jan 8, 2025 for continued non-compliance with $1.00 minimum bid price rule.
NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)
Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.
NeuroOne terminates loan agreement with Growth Opportunity Funding effective Nov 7, 2024
NeuroOne and Growth Opportunity Funding, LLC mutually terminated the Loan and Security Agreement dated August 2, 2024 on November 7, 2024.
NeuroOne expands Zimmer Biomet distribution deal for OneRF Ablation System; $3M upfront
Zimmer Biomet gets exclusive US and certain OUS distribution rights for OneRF Ablation System.
NeuroOne amends CEO & three other execs' change-in-control severance benefits
CEO Rosa: 2.0x base salary + 2.0x target bonus lump sum, full equity vest, 24-month COBRA upon qualifying termination.
Product revenue $826K in Q3 FY2024 vs $630K in Q3 FY2023 (+31%); net loss $2.8M vs $3.5M.
NeuroOne raises ~$2.65M in private placement and secures $3M debt facility
Private placement of 2,944,446 shares and warrants for 2,208,333 shares at $0.90/unit, gross ~$2.65M.
NeuroOne receives Nasdaq delisting notice for bid price below $1.00 for 30 days
Closing bid price of common stock below $1.00 for 30 consecutive business days triggered Nasdaq minimum bid price deficiency.
NeuroOne amends bylaws: reduces stockholder quorum to one-third, updates proxy rules
Stockholder quorum reduced from majority to one-third of outstanding voting power.
NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched
Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.
NeuroOne Medical Technologies starts limited commercial launch of OneRF Ablation System
OneRF System is FDA 510(k)-cleared for creating RF lesions in nervous tissue for functional neurosurgery.
Paul Buckman elected Class I director: 5,804,908 for, 1,363,109 withheld, 8,614,407 broker non-votes.
NeuroOne Q1 revenue jumps to $978k; OneRF Ablation System receives FDA clearance
Product revenue $978k in Q1 fiscal 2024, up from $115k in Q1 2023.
NeuroOne Q4 product revenue $742K vs $69K YoY; net loss $3.1M; FDA clears OneRF Ablation System
Product revenue $742K (Q4) vs $69K YoY; full year $1.952M vs $171K.
NeuroOne receives FDA 510(k) clearance for OneRF Ablation System; plans H1 2024 launch
FDA 510(k) clearance for OneRF Ablation System to create RF lesions in nervous tissue for functional neurosurgical procedures.
NeuroOne receives Notice of Allowance for drug-delivery neural probe patent
USPTO issued Notice of Allowance for Patent App. 16/812,702 covering electrodes that deliver treatment agent to brain target.
NeuroOne appoints medtech exec Christopher Volker as COO; inducement plan expanded by 420,350 shares
Christopher Volker appointed COO effective Nov 10, 2023; formerly Head of Commercial Integration at Abbott and VP/GM International at Cardiovascular Systems.
NeuroOne responds to FDA questions on OneRF Ablation System 510(k); expects feedback in 30 days
Company responded to FDA questions on its 510(k) submission for the OneRF Ablation System.
NeuroOne Q3 FY2023 product revenue $630K, up from $32K; net loss $3.5M
Product revenue $630K in Q3 FY2023 vs $32K YoY; collaboration revenue $1.46M in 9M.
NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share
Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.
NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched
Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.
NeuroOne holds annual meeting; elects directors Mathiesen and Andrle, ratifies auditor
Annual meeting held March 16, 2023; 9,719,474 shares (59.83%) represented.
NeuroOne confirms no cash deposits or securities at Silicon Valley Bank
Company states it holds no cash or securities at Silicon Valley Bank.
NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode
Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.
NeuroOne Medical appoints American Stock Transfer as new transfer agent
Appointed American Stock Transfer & Trust Company effective January 9, 2023.
the Board announced that Christopher Volker, the Company’s Chief Operating Officer, will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026.
On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company’s Chief Financial Officer.
Christopher R. Volker, age 52, has been appointed as the Chief Operating Officer of the Company, effective on November 10, 2023.
Max materiality 0.80 · Median 0.65 · Most common event other_material